PRESS RELEASE

from Arix Bioscience PLC (isin : GB00BD045071)

Unaudited NAV for March 2023

Arix Bioscience PLC (ARIX)
Unaudited NAV for March 2023

17-Apr-2023 / 07:00 GMT/BST


 

Arix Bioscience plc

 

Unaudited NAV for March 2023

 

LONDON, 17 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 March 2023 as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31 March 2023

(unaudited)

£42.9m

£66.6m

£108.7m

£3.1m

£221.3m

£1.71

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 



Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


ISIN:GB00BD045071
Category Code:MSCL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories:3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:237106
EQS News ID:1608427

 
End of AnnouncementEQS News Service

fncls.ssp?fn=show_t_gif&application_id=1608427&application_name=news&site_id=symex
See all Arix Bioscience PLC news